Total | non-protocol | protocol | p | ||||
---|---|---|---|---|---|---|---|
(N = 158) | (N = 14) | (N = 144) | |||||
Age,median (IQR) | 68.5 | (56–74.3) | 60 | (50–73) | 68 | (56–74.8) | 0.263 |
Sex, n (%) | |||||||
Male | 107 | (68) | 10 | (71) | 97 | (67) | |
Female | 51 | (32) | 4 | (29) | 47 | (33) | 0.756 |
BMI (kg/m2)(IQR) | 25 | (22.8–259) | 24.1 | (20.6–28.2) | 25.2 | (22.9–27.9) | 0.345 |
P/F ratio after intubation (IQR) | 203 | (164–259) | 213 | (182.5–267) | 198 | (162.5–259.5) | 0.343 |
APACHE ΙΙ score (IQR) | 12 | (9–14) | 9 | (5–13) | 12 | (9–15) | 0.019 |
pre-existing diabetes, n (%) | 44 | (27.8) | 1 | (7) | 43 | (29.9) | 0.07 |
HbA1c, median (IQR) | 6.2 | (5.8–7.2) | 6.6 | (6.0–7.8) | 6.2 | (5.8–7.2) | 0.233 |
Intubation, n (%) | 158 | (100) | 14 | (100) | 144 | (100) | - |
Anti-viral drug | |||||||
before admission | |||||||
Favipiravir, n(%) | 51 | (32) | 0 | (0) | 51 | (35) | - |
after admission | |||||||
Favipiravir, n(%) | 86 | (54) | 14 | (100) | 72 | (50) | - |
Remdesivir, n(%) | 9 | (6) | 0 | (0) | 9 | (6) | - |
Steroid treatment | |||||||
before admission | |||||||
Dexamethasone, n (%) | 57 | (36) | 0 | (0) | 57 | (40) | - |
Methylprednisolone, n (%) | 34 | (22) | 0 | (0) | 34 | (24) | - |
after admission | |||||||
Methylprednisolone, n (%) | 155 | (98) | 14 | (100) | 141 | (98) | |
ECMO, n (%) | 2 | (1) | 1 | (7) | 1 | (1) | |
Mortality, n (%) | 20 | (13) | 1 | (7) | 19 | (13) | 0.516 |